ReviewJournal of clinical medicine2021
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The impact of cancer on the severity of disease in patients affected with COVID-19: an umbrella review and meta-meta-analysis of systematic reviews and meta-analyses involving 1,064,476 participants.Clinical and experimental medicine · 2023Pooled it
- Predictive value of C-reactive protein for disease severity and survival in COVID-19 patients: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Presepsin levels and COVID-19 severity: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Exploratory Analysis of Serum IGF-I Levels and Symptom Trajectories in Long COVID During the Omicron Period.Journal of clinical medicine · 2026Article
- Update on andrological effects of SARS-CoV-2 infection and COVID-19: An overview review.Andrology · 2025Review
- COVID-19 vaccines and blood glucose control: Friend or foe?Human vaccines & immunotherapeutics · 2024Review
- Reevaluation of prognostic and severity indicators for COVID-19 patients in the emergency department.Annals of medicine · 2024Article
- Mass Spectrometry-Based Metabolomics Reveals a Salivary Signature for Low-Severity COVID-19.International journal of molecular sciences · 2024Article
- Article
- Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study.Diagnostics (Basel, Switzerland) · 2024Article
- Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients.Critical care science · 2024Article
- Predicting Factors of Worse Prognosis in COVID-19: Results from a Cross-sectional Study on 52 Inpatients Admitted to the Internal Medicine Department.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients.Hepatology international · 2023Observational
- Inflammatory and Infectious Disorders in Endocrine Pathology.Endocrine pathology · 2023Review
- SARS-CoV-2 Affects Thyroid and Adrenal Glands: AnBiomedicines · 2023Article
- Exploring hematic crasis variations in cancer patients following SARS-CoV-2 vaccination: a real-practice study.Infectious agents and cancer · 2023Article
- Review
- COVID in 2022. Clinical risk management of sars-cov-2 positive patients admitted to an internal medicine ward.Clinical and experimental medicine · 2023Article
- Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing's disease: a monocentric experience in Southern Italy.Journal of endocrinological investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe review aimed to summarize advances in the topic of endocrine diseases and coronavirus disease 2019 (COVID-19).
methodsScientific and institutional websites and databases were searched and data were collected and organized, when plausible, to angle the discussion toward the following clinical issues. (1) Are patients with COVID-19 at higher risk of developing acute or late-onset endocrine diseases or dysfunction? (2) May the underlying endocrine diseases or dysfunctions be considered risk factors for poor prognosis once the infection has occurred? (3) Are there defined strategies to manage endocrine diseases despite pandemic-related constraints? Herein, the authors considered only relevant and more frequently observed endocrine diseases and disorders related to the hypothalamic-pituitary region, thyroid and parathyroid glands, calcium-phosphorus homeostasis and osteoporosis, adrenal glands, and gonads. Main. Data highlight the basis of some pathophysiological mechanisms and anatomical alterations of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-induced endocrine dysfunctions. Some conditions, such as adrenal insufficiency and cortisol excess, may be risk factors of worse clinical progression once the infection has occurred. These at-risk populations may require adequate education to avoid the SARS-CoV-2 infection and adequately manage medical therapy during the pandemic, even in emergencies. Endocrine disease management underwent a palpable restraint, especially procedures requiring obligate access to healthcare facilities for diagnostic and therapeutic purposes. Strategies of clinical triage to prioritize medical consultations, laboratory, instrumental evaluations, and digital telehealth solutions should be implemented to better deal with this probably long-term situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.